칼프로텍틴 대 락토페린: 대변 검사 선택

카테고리
조항
장 건강 검사 해석 2026년 업데이트 환자 친화적

Both tests detect neutrophil-driven intestinal inflammation, but calprotectin is usually the more useful quantitative monitoring tool. The right result is one that changes the next clinical decision—not one that labels you with IBD.

📖 약 11분 📅
📝 게시됨: 🩺 의학적 검토: ✅ 근거 기반
⚡ 간단한 요약 v1.0 —
  1. Calprotectin below 50 µg/g is generally reassuring in adults with suspected IBS when there are no alarm features.
  2. Lactoferrin is a neutrophil protein; many quantitative assays use less than 7.25 µg/g as negative, but laboratory cutoffs vary.
  3. High stool markers indicate intestinal inflammation, not a specific diagnosis; infection, NSAIDs, diverticulitis and colorectal neoplasia can raise both.
  4. 경계(보더라인) 칼프로텍틴 of 50–150 µg/g often merits a repeat sample after 2–6 weeks rather than immediate colonoscopy.
  5. Calprotectin above 250 µg/g increases concern for active mucosal inflammation and usually prompts clinical review, stool infection testing or endoscopy planning.
  6. 정상 결과 make active colonic IBD less likely but cannot reliably exclude isolated small-bowel Crohn’s disease.
  7. IBD monitoring uses symptoms plus biomarkers, CRP, anemia markers, imaging and endoscopy; neither stool marker independently diagnoses a flare.
  8. 응급 증상 such as black stool, persistent visible blood, fever, severe pain, fainting or dehydration need medical assessment regardless of a marker result.

Which stool marker should you choose first?

Fecal calprotectin is usually the first-choice stool inflammation marker because it is widely available, quantitative, and has the strongest role in separating likely inflammatory bowel disease from functional bowel symptoms. 대변 락토페린 검사 results are a sensible alternative when that is the locally validated assay, but ordering both at the outset rarely changes care.

Calprotectin vs lactoferrin laboratory proteins shown beside an intestinal cross-section
그림 1: Two neutrophil-derived stool markers shown beside the colonic lining.

For a person with 6 weeks of loose stools, cramping, and no weight loss or rectal bleeding, I would generally begin with calprotectin plus targeted infection testing rather than colonoscopy. A result below 50 µg/g makes significant colonic inflammation less likely, while a clearly elevated result provides a reason to look further. The AGA guideline for chronic watery diarrhoea supports calprotectin or lactoferrin as screening tests for inflammatory conditions (Smalley et al., 2019).

Choose lactoferrin when your gastroenterology service uses it consistently, when the laboratory reports a validated quantitative value, or when it is bundled with an infectious diarrhoea work-up. Do not choose it because it sounds more specific: both proteins are released when neutrophils enter the bowel lumen. The practical issue is whether your clinician can compare the result with your prior samples using the same assay.

칸테스티는 AI 혈액검사 분석기 that places related results such as hemoglobin, CRP, albumin and iron indices alongside a stool-marker report; it does not replace the stool assay or a clinician’s diagnosis. If fatigue accompanies diarrhoea, a blood test for diarrhoea can help identify dehydration, anemia, or electrolyte loss that changes urgency.

A useful rule of thumb

Use one validated marker first, repeat the same marker when a result is borderline or when monitoring treatment, and reserve dual testing for a specific gastroenterology question. Changing assay halfway through follow-up creates apparent trends that may be laboratory noise rather than biology.

What fecal calprotectin actually detects

Calprotectin measures a calcium- and zinc-binding protein released predominantly from neutrophils in the intestinal tract. A higher stool concentration reflects neutrophil migration into the gut, which is common in active IBD but also occurs with several non-IBD conditions.

Fecal calprotectin test sample tray with an immunoassay cartridge in clinical laboratory
그림 2: A quantitative stool extraction workflow used for calprotectin measurement.

Calprotectin is the S100A8/S100A9 protein complex, and it remains relatively stable in stool for several days at room temperature—one reason it works well as a home collection test. Its biological strength is locality: unlike CRP, it reflects cellular activity in the intestinal lumen rather than a whole-body acute-phase response. A normal CRP therefore does not cancel a high calprotectin result.

In adult practice, laboratories commonly classify less than 50 µg/g as normal and more than 150–250 µg/g as increasingly compatible with active intestinal inflammation. These are decision thresholds, not universal biological borders. Some European services use 100 µg/g as the referral threshold, while pediatric and assay-specific reference intervals can differ substantially.

I have seen a 28-year-old with a calprotectin of 680 µg/g, a normal CRP, and ultimately ulcerative colitis limited to the rectum and sigmoid colon. That pattern is not unusual: local mucosal inflammation can be active without a strong systemic signal. Our fecal calprotectin range guide explains why the laboratory’s own method and units should stay attached to every result.

What fecal lactoferrin detects differently

Lactoferrin detects another neutrophil-derived protein and answers nearly the same biological question as calprotectin: is there active intestinal neutrophil inflammation? It does not identify ulcerative colitis, Crohn’s disease, bacterial colitis, or another cause on its own.

Lactoferrin protein molecules near intestinal neutrophils in medical cellular illustration
그림 3: Lactoferrin release from neutrophils during an intestinal tissue response.

Lactoferrin is an iron-binding glycoprotein stored in neutrophil secondary granules and released during activation. A positive qualitative fecal lactoferrin test is useful because it argues against uncomplicated IBS in the right clinical setting. Quantitative assays vary: one commonly used method defines a negative value as less than 7.25 µg/g, so never apply a calprotectin cutoff to a lactoferrin report.

The evidence does not show that lactoferrin is categorically superior. In a diagnostic meta-analysis, Wang and colleagues found fecal lactoferrin had pooled sensitivity of 82% and specificity of 95% for distinguishing IBD from non-IBD controls, although accuracy estimates shift with disease prevalence and study design (Wang et al., 2015). That impressive specificity still does not convert a positive result into an IBD diagnosis.

A positive lactoferrin result is especially worth discussing when diarrhoea began abruptly after travel, antibiotics, contaminated food exposure, or contact with someone unwell. In those situations, clinicians usually add pathogen testing rather than jumping straight to an IBD label. Our guide to 대변배양 결과 covers what a negative or mixed-growth report can and cannot settle.

How to read cutoffs without overreacting

A calprotectin value below 50 µg/g is usually normal for adults, 50–150 µg/g is often an indeterminate zone, and values above 250 µg/g raise concern for active inflammation. Lactoferrin uses assay-specific cutoffs, commonly a qualitative positive or a quantitative threshold near 7.25 µg/g.

Calprotectin threshold comparison represented by stool assay wells and color gradation
그림 4: Quantitative zones help guide retesting and referral decisions.

The 50 µg/g calprotectin threshold is designed for sensitivity: it catches most clinically significant inflammatory disease at the cost of some false positives. The 250 µg/g threshold is more useful for specificity and for monitoring established IBD. Between them lies the frustrating middle, where medication exposure, recent gastroenteritis, age, and trajectory matter more than a single number.

A change from 72 to 94 µg/g is often less meaningful than a change from 85 to 430 µg/g, particularly if both samples were tested by the same laboratory. Stool consistency can influence extraction and biological variation is real. Dr. Thomas Klein’s practical advice is to record NSAID use, recent infection, menstrual contamination, and collection date before interpreting a modest rise.

For a disciplined approach to serial values, compare the sample date with symptoms and related labs rather than treating every flagged result as disease progression. Our 혈액검사 추세 가이드 explains the same principle of reference change and analytic variation in laboratory medicine.

대개 안심할 만함 <50 µg/g calprotectin Active colonic IBD is less likely in adults without alarm symptoms.
경계 구간 50–150 µg/g calprotectin Review NSAIDs, infection and symptoms; repeat testing is often appropriate.
명확히 상승 150–250 µg/g calprotectin Persistent elevation warrants clinical assessment and often further investigation.
현저히 높음 >250 µg/g calprotectin Suggests active mucosal inflammation but still requires cause-specific evaluation.

Why both markers can be high without IBD

Elevated stool inflammation markers occur with enteric infection, NSAID exposure, diverticulitis, colorectal neoplasia, microscopic colitis and IBD. The result confirms an inflammatory signal; it does not disclose the cause, location, duration, or severity by itself.

Clinical consultation reviewing anti-inflammatory medication and a stool inflammation report
그림 5: Medication history can materially alter interpretation of a raised marker.

Non-steroidal anti-inflammatory drugs can raise fecal calprotectin, sometimes substantially, by increasing intestinal permeability and causing small mucosal injuries. Ibuprofen, naproxen and diclofenac matter; a clinician may suggest withholding them if medically safe before repeating the test. Do not stop prescribed aspirin, anticoagulants, or pain medicines without asking the prescriber first.

Acute bacterial gastroenteritis may produce calprotectin values above 500 µg/g and a positive lactoferrin, which is why a stool pathogen panel can be more informative than an urgent colonoscopy in the first days of illness. Conversely, giardiasis may cause prolonged diarrhoea with less striking neutrophilic marker elevation. The symptom timeline often carries more diagnostic weight than patients expect.

칸테스티는 AI lab test interpretation service that can flag an inflammation pattern such as low hemoglobin, low albumin, thrombocytosis and raised CRP for clinician review, but those blood findings do not prove the source is intestinal. For people with blood in the stool, FIT follow-up and colonoscopy timing is a separate issue from calprotectin and should not be delayed.

When a normal result can still miss disease

Normal calprotectin or lactoferrin makes active colonic inflammation less likely, but it cannot fully exclude Crohn’s disease, particularly mild or isolated small-bowel disease. A normal result also does not explain persistent weight loss, iron-deficiency anemia, nocturnal diarrhoea, or recurrent visible bleeding.

Small bowel cross-section showing patchy Crohn's disease activity beyond stool marker reach
그림 6: Patchy small-bowel activity may produce a less conspicuous stool signal.

Small-bowel Crohn’s disease can shed less neutrophil protein into a stool sample than extensive colitis, especially when lesions are proximal or mild. This is one reason symptoms and alarm features overrule a reassuring number. The ECCO-ESGAR diagnostic guideline recommends integrating biomarkers with ileocolonoscopy and cross-sectional imaging when IBD remains clinically suspected (Maaser et al., 2019).

A 46-year-old with calprotectin of 38 µg/g, ferritin of 7 ng/mL, and progressive fatigue deserves evaluation for gastrointestinal blood loss or malabsorption even if bowel frequency is normal. In my experience, the combination of iron deficiency and unexplained symptoms is much more consequential than a single low stool marker. Read our low ferritin and gut clues for the usual next laboratory questions.

Celiac disease, bile acid diarrhoea, pancreatic insufficiency and many medication effects may cause symptoms with normal stool inflammation markers. A normal test is therefore a fork in the road toward non-inflammatory diagnoses, not a declaration that symptoms are psychological or unimportant.

What to do with a borderline calprotectin result

A borderline fecal calprotectin result of 50–150 µg/g is commonly repeated after 2–6 weeks if symptoms are stable and there are no alarm features. The repeat should use the same laboratory method and should be timed away from a recent gastrointestinal infection where possible.

Home stool sample collection kit beside calendar and medication review notes
그림 7: A repeat sample is most informative when collection conditions are documented.

Before retesting, clinicians review NSAIDs, proton-pump inhibitors, antibiotics, acute infections, strenuous endurance exercise and age-related risk. There is no universally agreed washout interval for every medicine. A pragmatic plan is often 2 weeks after an acute illness has settled, provided symptoms do not signal a need for earlier care.

If the repeat falls from 118 to 32 µg/g and symptoms settle, invasive testing may be avoidable. If it rises from 96 to 310 µg/g, the direction adds useful evidence even before an endoscopy result arrives. This is why a single borderline value should rarely trigger panic—or false reassurance.

우리의 borderline calprotectin follow-up guide lays out the questions to bring to a primary-care or gastroenterology appointment. A short symptom diary with stool frequency, nighttime waking, fever and medication dates is usually more useful than obsessively checking food triggers.

How clinicians use markers after IBD is diagnosed

In established IBD, calprotectin is most useful for tracking objective intestinal inflammation and helping decide whether symptoms represent a flare, infection, IBS overlap, or treatment failure. Lactoferrin can also follow activity, but calprotectin has more guideline-supported thresholds for treat-to-target monitoring.

Gastroenterology clinic reviewing stool biomarker trend cards alongside blood laboratory results
그림 8: Serial biomarkers complement symptoms during IBD follow-up.

Symptoms and mucosal activity frequently diverge. A patient with ulcerative colitis may feel well while calprotectin climbs from 80 to 360 µg/g, or have urgent bowel motions from bile acid malabsorption while calprotectin remains 28 µg/g. The 2023 AGA ulcerative colitis biomarker guideline advises combining symptoms with biomarkers rather than relying on either alone (Singh et al., 2023).

For remission monitoring, many clinicians view less than 150 µg/g as reassuring, while more than 150 µg/g may warrant repeat testing, endoscopy, or treatment review depending on symptoms and prior disease behaviour. In active symptomatic ulcerative colitis, more than 250 µg/g supports ongoing inflammation. Cutoffs are guides, not instructions to alter biologic treatment without specialist input.

Kantesti AI는 AI 바이오마커 해석 플랫폼 that organizes blood-test trends around a patient’s reported treatment dates; it cannot assess stool endoscopic severity from a number alone. Patients taking biologics should also understand which blood safety tests monitor treatment and which symptoms require prompt contact with their IBD team.

How collection errors and timing affect results

Collection quality affects stool marker interpretation because a contaminated, delayed, or poorly sampled specimen can be rejected or produce a less reliable measurement. Most laboratories want a small stool portion placed into the supplied sterile container without toilet water or urine.

Hands placing stool sample into a sterile collection container using a clinical kit
그림 9: Clean collection reduces preventable sample rejection and ambiguity.

Loose stool is usually acceptable for calprotectin and lactoferrin testing; do not wait for a formed sample if diarrhoea is the clinical problem. Avoid collecting from toilet water, and tell the laboratory if the sample includes visible menstrual blood. Storage instructions vary by kit, but many allow short room-temperature transport because calprotectin is comparatively stable.

Sampling a day after a marathon, a bout of gastroenteritis, or colonoscopy bowel preparation may answer the wrong question. Endurance exercise can transiently increase gut permeability and provoke gastrointestinal symptoms. If you are an endurance athlete without red flags, consider timing collection away from a major event; our 지구력 운동선수 검사 가이드에서 다룹니다. explains why context changes test interpretation.

The thing is, a perfect collection does not make a nonspecific biomarker specific. A high-quality sample improves confidence in the measurement; it cannot replace the clinical history, examination, and differential diagnosis.

Which blood tests make a stool marker more useful

A CBC, CRP, ferritin, albumin, kidney function and celiac serology often add more clinical value to a raised stool marker than ordering a second stool inflammation protein. The concerning pattern is not any one abnormality but several results that point toward inflammation, malabsorption, or blood loss.

Laboratory blood panel results arranged with a calprotectin stool marker report
그림 10: Blood markers add systemic context to an intestinal inflammation result.

Low hemoglobin, ferritin below 15 ng/mL, albumin below the laboratory reference range, raised platelets, or raised CRP can strengthen concern for clinically meaningful bowel disease. None is diagnostic of IBD. In fact, CRP may remain normal in mild ulcerative colitis, and ferritin can look falsely normal when inflammation raises it as an acute-phase protein.

칸테스티는 AI 기반 혈액검사 분석 도구 that reads a CBC, iron studies and CRP in the same clinical frame, including whether a changing hemoglobin level might justify earlier review. Dr. Thomas Klein routinely cautions that an isolated CRP of 12 mg/L is nonspecific, whereas CRP 12 mg/L plus falling albumin and a calprotectin of 740 µg/g is a much more actionable cluster.

For patients whose iron values seem contradictory, our iron studies research guide explains transferrin saturation and ferritin during inflammation. A CBC result guide can also help you identify whether anemia is microcytic, inflammatory, or mixed.

When ordering both tests may be reasonable

Ordering calprotectin and lactoferrin together is usually unnecessary, but it can be reasonable when a specialist is reconciling discordant symptoms, a prior assay cannot be repeated, or a local pathway requires confirmation. Concordant results modestly increase confidence in an inflammatory signal; discordant results usually trigger review, not arithmetic averaging.

Two separate stool inflammation assay cartridges compared in a gastroenterology laboratory
그림 11: Different assay platforms should not be treated as interchangeable trend points.

A high calprotectin with negative lactoferrin may reflect assay timing, a result near the cutoff, specimen heterogeneity, or analytical differences. A low calprotectin with positive lactoferrin deserves the same disciplined response: verify collection, review the exact assay, check symptoms and test for infection when appropriate. Neither combination has a validated shortcut to diagnosis.

Dual testing can also be useful in research settings where a protocol prespecifies both biomarkers. That is different from routine patient care, where duplicate testing can add cost without improving decisions. Ask the ordering clinician a simple question: “What will we do differently if the second test is positive?”

If a report looks internally inconsistent, use our 정성적 대 정량적 검사 안내 to understand why “positive” and “high” are not interchangeable laboratory statements. Consistency of method matters more than collecting every available marker.

What actually confirms or excludes IBD

IBD is diagnosed through a synthesis of symptoms, ileocolonoscopy with tissue sampling, histology, laboratory tests, and sometimes MRI or CT enterography—not from calprotectin or lactoferrin alone. Stool markers help decide who needs these investigations and whether inflammation may be changing over time.

Ileocolonoscopy pathway represented by colon anatomy and clinical diagnostic instruments
그림 12: Endoscopy and tissue examination establish the diagnosis beyond biomarker screening.

Colonoscopy allows direct assessment of the terminal ileum and colon and permits tissue examination for chronic inflammatory features, infection, microscopic colitis, dysplasia, and other causes. Imaging is particularly valuable when Crohn’s disease may involve small bowel beyond the reach of a standard colonoscopy. A stool marker is a triage signal, not a microscopic diagnosis.

Do not confuse a fecal immunochemical test with either inflammatory marker. FIT detects human hemoglobin and is used primarily in colorectal cancer screening or lower-GI bleeding pathways, whereas calprotectin and lactoferrin detect neutrophil products. Our comparison of FIT and FOBT explains why a negative inflammation marker does not substitute for recommended cancer screening.

As of September 4, 2026, no major gastroenterology guideline recommends diagnosing Crohn’s disease or ulcerative colitis from a single stool biomarker threshold. That restraint protects patients from both missed disease and unnecessary lifelong diagnostic labels.

Symptoms that outweigh any stool test result

Persistent visible rectal bleeding, black tarry stool, severe abdominal pain, fever, fainting, dehydration, rapidly worsening weakness, or unintended weight loss need timely medical assessment regardless of calprotectin or lactoferrin. A normal result should never be used to wait out a potentially urgent symptom pattern.

Patient symptom diary and urgent clinical assessment pathway in a calm medical setting
그림 13: Alarm symptoms require clinical triage even when a stool marker is low.

The urgent concern is physiology, not the label on a laboratory report. Frequent watery diarrhoea can produce low potassium, acute kidney injury, and orthostatic symptoms before an inflammation marker returns. Adults with inability to keep fluids down, confusion, fainting, or minimal urine output should seek urgent care.

New bowel symptoms after age 50, a strong family history of colorectal cancer, and iron-deficiency anemia alter the threshold for colon evaluation even when calprotectin is low. A stool marker does not assess cancer risk comprehensively. Our mucus in stool red-flag guide distinguishes common benign patterns from symptoms that need examination.

Children, pregnant people, older adults, and people using immune-suppressing medicines need individualized triage because their baseline risks differ. If you are unsure whether symptoms are urgent, contacting a local clinician or urgent-care service is safer than trying to interpret a number in isolation.

A practical conversation to have after your result

The most useful follow-up question is: “Does this result change my need for infection testing, repeat testing, imaging, or endoscopy?” Bringing the exact value, assay name, symptom timeline, medicines, and previous results makes that conversation faster and more clinically precise.

Over-shoulder clinical discussion of stool inflammation results and symptom timeline
그림 14: A structured symptom and medication history turns a biomarker into a decision.

Bring a list of the previous 14 days: stool frequency, overnight symptoms, fever, weight change, travel, antibiotics, NSAIDs, and family history. A calprotectin of 180 µg/g after a 3-day febrile diarrhoeal illness calls for a different plan than the same result after 4 months of nocturnal diarrhoea and weight loss.

Kantesti AI can help you organize accompanying blood reports before an appointment, but diagnosis and treatment decisions belong with the clinician who can examine you and arrange definitive testing. Our 의학적 검증 접근법은 explains how clinical oversight and source checking are built into responsible laboratory interpretation.

For complex cases, ask who will own the follow-up and when you should expect a repeat result or referral decision. The clinicians on our 의료 자문 위원회 emphasize that a documented plan beats a vague instruction to “recheck later,” especially when inflammation markers and anemia move in the same direction.

The decision-focused bottom line

Choose calprotectin first in most settings, use lactoferrin when it is your service’s validated alternative, and do not assume either result diagnoses IBD. A low result shifts attention toward functional and non-inflammatory causes, while a persistently high result identifies people who may need infection testing, specialist review, or endoscopy.

For uncomplicated chronic diarrhoea, one normal marker—calprotectin below 50 µg/g or a negative lactoferrin according to that laboratory—can reduce the likelihood of active inflammatory disease. For a value above 250 µg/g or a positive lactoferrin with persistent symptoms, the next question is cause, not certainty. Infection, medicine exposure, IBD, and other inflammatory conditions remain on the list.

Most patients find the ambiguity hardest in the 50–150 µg/g calprotectin zone. In my experience, the best next step is usually a carefully timed repeat, not a dietary cleanse, self-directed steroid use, or an internet diagnosis. Keep the same laboratory where feasible so the trend is interpretable.

Kantesti의 AI 기술 가이드 describes how our systems preserve laboratory context while highlighting questions for medical review. The safe use of any AI interpretation is the same here: use it to prepare for a better clinical conversation, never to override red flags or replace diagnostic care.

자주 묻는 질문

염증성 장질환(IBD) 진단에 칼프로텍틴이 락토페린보다 더 나은가요?

칼프로텍틴은 정량 검사가 널리 이용 가능하고 50 µg/g 미만 및 250 µg/g 초과와 같이 일반적으로 사용되는 모니터링 기준치가 있기 때문에 염증성 장 질환(IBD)이 의심될 때 보통 선호됩니다. 락토페린도 유용한 호중구 유래 대변 표지자이며, 실험실에서 검증된 분석법을 사용할 경우 잘 수행될 수 있습니다. 감염, NSAIDs, 게실염 및 기타 장 질환이 두 표지자 모두를 상승시킬 수 있으므로 어느 표지자도 IBD를 확진하지는 못합니다. 더 나은 검사는 보통 임상의가 증상과 함께 해석하고 동일한 실험실 방법을 사용하여 반복할 수 있는 검사입니다.

어느 정도의 칼프로텍틴 수치가 우려스러운가요?

50 µg/g 미만의 대변 칼프로텍틴 수치는 경고 증상이 없는 성인에서는 일반적으로 안심할 수 있으며, 50–150 µg/g는 종종 경계선으로 간주되어 2–6주 후에 반복할 수 있습니다. 150–250 µg/g 이상의 수치는 장 염증에 대해 더 우려되며, 250 µg/g 이상의 수치는 일반적으로 임상적 평가 또는 추가 검사를 유발합니다. 정확한 조치는 검사법, 증상, 연령, NSAID 사용 여부 및 수치가 상승하는지 여부에 따라 달라집니다. 급성 세균성 설사 후 600 µg/g의 수치는 만성 증상이 수개월 동안 지속될 때의 600 µg/g와 다른 의미를 가질 수 있습니다.

과민성 대장 증후군(IBS)이 높은 칼프로텍틴 또는 락토페린 수치를 유발할 수 있나요?

합병증이 없는 과민성 대장 증후군(IBS)은 일반적으로 장내 호중구 유발 염증을 일으키지 않기 때문에 대변 칼프로텍틴 또는 락토페린 수치가 상승하지 않습니다. 50~150 µg/g 사이의 경미한 칼프로텍틴 상승은 최근 감염, NSAID 사용, 노화 관련 요인 또는 검사 방법의 변동으로 인해 발생할 수 있으므로 IBS를 자동으로 배제하지는 않습니다. 250 µg/g 이상의 락토페린 또는 칼프로텍틴 양성 반응은 IBS를 가정하기보다는 염증성 또는 감염성 원인에 대한 평가를 유도해야 합니다. IBS와 염증성 장 질환(IBD)은 함께 발생할 수 있으며, 이는 증상과 추세가 중요한 또 다른 이유입니다.

Can a normal calprotectin rule out Crohn's disease?

정상 칼프로텍틴 수치는 활동성 대장 염증성 장질환(IBD)의 가능성을 낮추지만, 특히 경증 또는 국소적인 소장 크론병의 경우, 크론병을 완전히 배제할 수는 없습니다. 50 µg/g 미만의 수치는 철결핍성 빈혈, 체중 감소, 야간 설사, 지속적인 출혈 또는 강력한 가족력과 같은 경고 증상을 무시해서는 안 됩니다. 임상적 의심이 높을 경우 의사는 회맹대장내시경, MR 장 촬영술 또는 캡슐 내시경 평가를 사용할 수 있습니다. 이 결과는 최종 배제 검사라기보다는 확률을 조정하는 하나의 증거 조각으로 취급하는 것이 가장 좋습니다.

Should I repeat a borderline calprotectin result?

A borderline calprotectin result of 50–150 µg/g is often repeated after 2–6 weeks when symptoms are stable and there are no alarm features. Before repeating, clinicians commonly review recent gastroenteritis, NSAID use, antibiotics and collection conditions, because each can influence the value. Use the same laboratory assay if possible, since results from different methods may not be directly comparable. A rising result toward or above 250 µg/g generally carries more clinical weight than a stable low-grade elevation.

Can antibiotics affect fecal calprotectin and lactoferrin?

Antibiotics can affect stool inflammation markers indirectly by treating, triggering, or coinciding with infectious diarrhoea and by altering the intestinal microbiome. A person with antibiotic-associated diarrhoea should be assessed for causes such as Clostridioides difficile rather than interpreting a raised calprotectin or positive lactoferrin as IBD. There is no reliable universal number of days to wait after antibiotics before testing; timing depends on symptoms and the clinical question. Persistent diarrhoea, fever, or abdominal pain after antibiotics needs clinician-led testing rather than self-treatment.

오늘 AI 기반 혈액검사 분석 받기

즉시 정확한 검사 분석을 위해 Kantesti를 신뢰하는 전 세계 200만 명 이상의 사용자와 함께하세요. 혈액검사 결과를 업로드하고 몇 초 만에 15,000+ 바이오마커에 대한 포괄적인 해석을 받아보세요.

📚 참고된 연구 출판물

1

Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti LTD. (2026). 소변 검사에서의 유로빌리노겐: 2026년 완전 소변 분석 가이드. Zenodo.. Kantesti AI 의학 연구.

2

Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti LTD. (2026). Iron Studies Guide: TIBC, Iron Saturation & Binding Capacity. Zenodo.. Kantesti AI 의학 연구.

📖 외부 의학 참고문헌

3

스말리 W 등 (2019). AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults. Gastroenterology.

4

Maaser C et al. (2019). ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis.

5

Singh S et al. (2023). AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. Gastroenterology.

200만+분석된 테스트
127+국가
75+언어

⚕️ 의료 면책 조항

E-E-A-T 신뢰 신호

경험

의사가 주도하는 검사 해석 워크플로 임상 검토.

📋

전문적 지식

임상 맥락에서 바이오마커가 어떻게 거동하는지에 대한 검사실 의학 중심.

👤

권위

Dr. Thomas Klein이 작성했으며 Dr. Sarah Mitchell과 Prof. Dr. Hans Weber가 검토했습니다.

🛡️

신뢰성

경고를 줄이기 위한 명확한 후속 경로가 포함된 근거 기반 해석.

🏢 칸테스티 LTD 잉글랜드 & 웨일스에 등록 · 회사 번호. 17090423 런던, 영국 · 칸테스티.넷
blank
Prof. Dr. Thomas Klein에 의해

Thomas Klein 박사는 Kantesti AI의 최고 의료 책임자(CMO)로 재직 중인 보드 인증 임상 혈액종양내과 전문의입니다. 실험실 의학 분야에서 15년 이상의 경험을 보유하고 있으며, 혈액검사 결과의 AI 지원 해석에 큰 관심을 가지고 있습니다. 그는 새로운 기술을 일상적인 임상 진료와 연결하기 위해 노력합니다. 그의 관심 분야에는 생체표지자 분석, 임상 의사결정 지원 연구, 인구집단별 기준 범위 최적화가 포함됩니다. CMO로서 그는 플랫폼의 내부 벤치마킹에 대한 임상적 의견을 제공하고, Kantesti의 교육 보고서에 대한 의학적 품질에 대해 임상적 감독을 제공합니다.

답글 남기기

이메일 주소는 공개되지 않습니다. 필수 필드는 *로 표시됩니다